Endoscopic sleeve gastroplasty, or ESG, reduces stomach capacity by placing stitches through an endoscope passed through the mouth. Research on how quickly weight changes on a GLP-1 provides context for reading the follow-up periods. Two studies found more weight loss with ESG at six months, but used different medications and could not establish which treatment performs better over the long term.[1][2][3]
What the direct comparisons found
In a retrospective cohort of 150 adults, average total body weight loss at six months was 12.72% with ESG and 8.67% with oral semaglutide 14 mg. At 12 months, it was 11.92% and 10.91%, respectively (P = 0.41). During follow-up, 18 people stopped semaglutide and five ESG patients started it. The later comparison did not establish that outcomes were equivalent.[1]
In a separate randomized trial of 43 adults, weight loss was greater with ESG than liraglutide at three and six months. At 12 months the study found no statistically clear difference. Neither comparison evaluated an injectable semaglutide or tirzepatide regimen as the initial alternative to ESG.[1][2]
Results after an earlier sleeve gastrectomy
A retrospective study of treatment for weight regain after bariatric surgery included 22 people who had revisional ESG and 68 who received medication. At 12 months, average total weight loss was 13.4% after the procedure and 9.2% in the medication group (P = 0.07). The tirzepatide subgroup averaged 13.2%, but the study cannot establish equivalent effects.[4]
What the five-year cost model assumed
A 2024 U.S. health care model for adults with class II obesity used 2022 dollars and assumed an annual semaglutide price of $13,618. Under those assumptions, ESG cost $33,583 less over five years and produced 0.06 more modeled quality-adjusted life-years. The model estimated that different drug prices could change the comparison. Those are modeled health care costs and outcomes, rather than measured patient bills or trial results.[3]